Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Improving phosphate-binder therapy as a way forward.

Alastair J Hutchison1

  • 1Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK. alastair.hutchison@cmmc.nhs.uk

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
|May 6, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hyperphosphataemia in 2019: have we made progress?

Current opinion in nephrology and hypertension·2019
Same author

A randomized controlled trial of different serum phosphate ranges in subjects on hemodialysis.

BMC nephrology·2019
Same author

Lanthanum carbonate: safety data after 10 years.

Nephrology (Carlton, Vic.)·2016
Same author

Use of magnesium as a drug in chronic kidney disease.

Clinical kidney journal·2015
Same author

Enabling self-management: selecting patients for home dialysis?

NDT plus·2015
Same author

Novel phosphate binders: plus ça change, plus c'est la même chose.

Kidney international·2014

New phosphate binders are needed for end-stage renal disease patients due to side effects of traditional agents. Lanthanum carbonate shows promise as a safe and effective alternative, improving phosphorus control without hypercalcemia.

Area of Science:

  • Nephrology
  • Pharmacology

Background:

  • Traditional aluminium- or calcium-based phosphate binders for hyperphosphataemia in end-stage renal disease (ESRD) carry significant risks.
  • Aluminium agents can cause bone toxicity and encephalopathy; calcium agents increase hypercalcaemia and cardiovascular calcification risk.

Purpose of the Study:

  • To evaluate lanthanum carbonate as a novel, non-calcium, non-aluminium phosphate binder for hyperphosphataemia in ESRD patients.
  • To assess its efficacy, safety, and tolerability compared to existing treatments and placebo.

Main Methods:

  • Review of animal and clinical studies on lanthanum carbonate for hyperphosphataemia treatment.
  • Comparison of lanthanum carbonate's effects on serum phosphorus, calcium levels, and bone histology against placebo and calcium carbonate.

Related Experiment Videos

Main Results:

  • Lanthanum carbonate demonstrated significant reduction in serum phosphorus levels compared to placebo.
  • It showed comparable efficacy to calcium carbonate but required lower doses and avoided hypercalcaemia.
  • Lanthanum carbonate positively impacted bone histology without inducing low bone turnover.

Conclusions:

  • Lanthanum carbonate represents a significant advancement in managing hyperphosphataemia in ESRD.
  • It offers an effective and well-tolerated alternative to traditional binders, moving closer to an ideal phosphate binder profile.